Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma

뉴스 본문을 불러오고 있어요.

Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma | 웨이프 WAPE

Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma

기사 요약

관련 종목

댓글 —